EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Breast Cancer Stem Active Cobalt(III)‐Cyclam Complex Containing Flufenamic Acid with Immunogenic Potential

Jiaxin Fang, Owamagbe N Orobator, Chibuzor Olelewe, Ginevra Passeri, Kuldip Singh, Samuel G Awuah, Kogularamanan Suntharalingam iD

Angewandte Chemie International Edition · 2024

DOI: 10.1002/anie.202317940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2024. Verfasst von Jiaxin Fang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, University of Leicester, Leicester, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Coordination Complexes, Antineoplastic Agents, Heterocyclic Compounds. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, Rosetrees Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cytotoxic and immunogenic‐activating properties of a cobalt(III)‐cyclam complex bearing the non‐steroidal anti‐inflammatory drug, flufenamic acid is reported within the context of anti‐cancer stem cell (CSC) drug discovery. The cobalt(III)‐cyclam complex 1 displays sub‐micromolar potency towards breast CSCs grown in monolayers, 24‐fold and 31‐fold greater than salinomycin (an established anti‐breast CSC agent) and cisplatin (an anticancer metallopharmaceutical), respectively. Strikingly, the cobalt(III)‐cyclam complex 1 is 69‐fold and 50‐fold more potent than salinomycin and cisplatin towards three‐dimensionally cultured breast CSC mammospheres. Mechanistic studies reveal that 1 induces DNA damage, inhibits cyclooxygenase‐2 expression, and prompts caspase‐dependent apoptosis. Breast CSCs treated with 1 exhibit damage‐associated molecular patterns characteristic of immunogenic cell death and are phagocytosed by macrophages. As far as we are aware, 1 is the first cobalt complex of any oxidation state or geometry to display both cytotoxic and immunogenic‐activating effects on breast CSCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCoordination ComplexesAntineoplastic AgentsHeterocyclic CompoundsHumansFemaleCisplatinFlufenamic AcidCobaltCell Line, TumorNeoplastic Stem Cells

Stichwörter der Autor:innen

Cancer Stem CellsCobaltDamage-Associated Molecular PatternsImmunotherapeuticsNon-Steroidal Anti-Inflammatory Drugs

Substanzen

CisplatinFlufenamic AcidcyclamCoordination ComplexesCobaltAntineoplastic AgentsHeterocyclic Compounds

Autor:innen und Institutionen

  • School of Chemistry, University of Leicester, Leicester, UK.
  • Department of Chemistry, University of Kentucky, Lexington, KY, USA.
  • Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, USA.

ORCID-Profile: Kogularamanan Suntharalingam

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • Rosetrees Trust
  • National Cancer Institute
  • Engineering and Physical Sciences Research Council

Zitieren

APA

Fang, J., Orobator, O. N., Olelewe, C., Passeri, G., Singh, K., Awuah, S. G., & Suntharalingam, K. (2024). A Breast Cancer Stem Active Cobalt(III)‐Cyclam Complex Containing Flufenamic Acid with Immunogenic Potential. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202317940

Vancouver

Fang J, Orobator ON, Olelewe C, Passeri G, Singh K, Awuah SG, et al. A Breast Cancer Stem Active Cobalt(III)‐Cyclam Complex Containing Flufenamic Acid with Immunogenic Potential. Angewandte Chemie International Edition. 2024. doi:10.1002/anie.202317940

BibTeX
@article{Fang2024,
  author = {Fang, Jiaxin and Orobator, Owamagbe N and Olelewe, Chibuzor and Passeri, Ginevra and Singh, Kuldip and Awuah, Samuel G and Suntharalingam, Kogularamanan},
  title = {A Breast Cancer Stem Active Cobalt(III)‐Cyclam Complex Containing Flufenamic Acid with Immunogenic Potential},
  journal = {Angewandte Chemie International Edition},
  year = {2024},
  doi = {10.1002/anie.202317940}
}
Kostenlos starten →